Women with von Willebrand disease

I. Scharrer

doi:10.1055/s-0037-1619605

Hämostaseologie, Table of Contents

Hamostaseologie 2004; 24(01): 44-49
DOI: 10.1055/s-0037-1619605

Grußwort

Schattauer GmbH

Women with von Willebrand disease

Frauen mit von-Willebrand-Syndrom

Authors

I. Scharrer

¹University Hospital, Haemophilia Centre, Frankfurt/Main, Germany

Abstract

Summary

The clinical presentation of VWD shows sex-related differences of symptoms. In women the most typical symptoms are menorrhagia, bleeding during and after delivery or abortion and bleeding in connection with caesarean section or gynaecological surgery. Menorrhagia is one of the most common symptoms presented to gynaecologists. In 7-20% of menorrhagia the underlying cause is VWD, in our cohort of 185 women with menorrhagia the prevalence of VWD was even 32%. On the other hand in women with VWD menorrhagia with onset at the menarche can be found in 60-93%, influencing substantially their morbidity and quality of life. During pregnancy women with mild VWD experience a decrease of bleeding tendency due to an increase of endogenous VWF. But as the VWF concentration drops rapidly after delivery, the post-partum period is often associated with significant bleeding complications. In severe forms of VWD the bleeding risk is high during delivery and postpartum period. Laboratory monitoring and therapeutical measures should be continued for 8-10 days after delivery. During menopause the clinical situation improves for most of the women with mild or moderate VWD.

Zusammenfassung

Die klinischen Symptome des VWS unterscheiden sich geschlechtsspezifisch. Typisch für betroffene Frauen sind Menorrhagien, Blutungen während und nach Geburt oder Abort und Blutungskomplikationen bei Schnittentbindung oder gynäkologischen Eingriffen. Die Menorrhagie führt am häufigsten zur Vorstellung beim Gynäkologen. Bei 7-20% liegt der Menorrhagie ein VWS zu Grunde, bei unseren 185 Patientinnen mit Menorrhagie lag die Prävalenz des VWS sogar bei 32%. Andererseits findet man eine Menorrhagie bei 65-93% der Frauen mit VWS, was deren Lebensqualität erheblich beeinflusst. Während der Gravidität stellen Frauen mit mildem VWS eine Abnahme der Blutungstendenz fest, was auf einem Anstieg der VWF-Konzentration beruht. Da diese nach der Entbindung schnell wieder abfällt, treten in der postpartalen Phase häufig schwere Blutungen auf. Bei schweren Formen des VWS ist das Blutungsrisiko während der Geburt und der postpartalen Phase hoch. Die Laborkontrollen und therapeutischen Maßnahmen sollten postpartal für weitere 8-10 Tage fortgesetzt werden. Mit der Menopause verbessern sich die Blutungssymptome der meisten Frauen mit mildem und moderatem VWS.

Keywords

Menorrhagia - delivery - postpartum bleeding

Schlüsselwörter

Menorrhagie - Entbindung - postpartale Blutungen

Full Text

References

References
1 Alperin JB. Estrogens and surgery in women with von Willebrand’s disease. Am J Med 1982; 73: 367-71.
2 Beller FK, Ebert C. Effects of oral contraceptives on blood coagulation. A review. Obstet Gynecol Surv 1985; 40: 425-36.
3 Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001; 86: 714-5.
4 Bevan JA, Maloney KW, Hillery CA. et al. Bleeding disorders:A common cause of menorrhagia in adolescents. J Pediatr 2001; 138: 856-61.
5 Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: Randomized controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. Br Med J 1996; 313: 578-82.
6 Budde U, Schneppenheim R. Von Willebrand factor and von Willebrand disease. Rev Clin Exp Hematol 2001; 5: 335-68.
7 Caliezi C, Tsakiris DA, Behringer H. et al. Two consecutive pregnancies and deliveries in a patient with von Willebrand’s disease type 3. Haemophilia 1998; 4: 845-9.
8 Casonato A, Sartori MT, Bertomoro A. et al. Pregnancy-induced worsening of thrombo-cytopenia in a patient with type IIB von Willebrand’s disease. Blood Coagul Fibrinol 1991; 2: 33-40.
9 Conti M, Mari D, Conti E. et al. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986; 68: 282-5.
10 David JL, Gaspard UJ, Gillain D. et al. Hemostasis profile in women taking low-dose oral contraceptives. Am J Obstet Gynecol 1990; 163: 420-3.
11 Dennis MW, Clough V, Toh CH. Unexpected presentation of type 2N von Willebrand disease in pregnancy. Haemophilia 2000; 6: 696-7.
12 Dilley A, Drews C, Miller C. et al. Von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol. 2001; 97: 630-6.
13 Economides DL, Kadir RA. Inherited bleeding disorders in obstetrics and gynaecology. Br J Obstetrics Gynaecol 1999; 106: 5-13.
14 Edlund M, Blomback M, von Schoultz B. et al. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53: 234-8.
15 Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey. Thromb Haemost 1995; 74: 784-90.
16 Giles AR, Hoogendoorn H, Benford K. Type IIB von Willebrand’s disease presenting as thrombocytopenia during pregnancy. Br J Haematol 1987; 67: 349-53.
17 Güth U, Tsakiris DA, Reber A. et al. Sub- und postpartales Management von Patientinnen mit von Willebrand-Jürgens-Syndrom Typ 2B. Z Geburtsh Neonatol 2002; 206: 151-5.
18 Ieko M, Sakurama S, Sagawa A. et al. Effect of a factor VIII concentrate on type IIB von Willebrand’s disease-associated thrombocytopenia presenting during pregnancy in identical twin mothers. Am J Hematol 1990; 35: 26-31.
19 Kadir RA, Economides DL, Sabin CA. et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 485-9.
20 Kadir RA, Lee CA, Sabin CA. et al. Pregnancy in women with von Willebrand’s disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105: 314-21.
21 Kadir RA, Sabin CA, Pollard D. et al. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia 1998; 4: 836-41.
22 Kadir RA, Economides DL, Sabin CA. et al. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Haemophilia 1999; 5: 40-8.
23 Kadir RA, Aledort LM. Obstetrical and gynaecological bleeding: a common presenting symptom. Clin Lab Haematol 2000; 22 (Suppl. 01) 12-6 30-2.
24 Kadir RA, Economides DL, Lee CA. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a prospective randomized placebo-controlled crossover study. Haemophilia 2000; 6: 243 (abstract 10).
25 Kirtava A, Drews C, Lally C. et al. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand’s disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia 2003; 9: 292-7.
26 Kobrinsky N, Goldsmith J. Efficacy of Stimate^® (desmopressin acetate) nasal spray, 1,5 ng/mL, for the treatment of menorrhagia in women with inherited bleeding disorders. Blood 1997; 90 (10) (Suppl. 01) part 2 106b (abstract 3186).
27 Kouides PA. Females with von Willebrand disease: 72 years as the silent majority. Haemophilia 1998; 4: 665-76.
28 Kouides PA, Phatak P, Burkart P. et al. Gynaecological and obstetrical morbidity in women with type 1 von Willebrand disease: results of a patient survey. Haemophilia 2000; 6: 643-8.
29 Kouides PA. Obstetric and gynaecological aspects of von Willebrand disease. Bailliere’s Best Pract Res Clin Haematol 2001; 14: 381-99.
30 Kouides PA. Menorrhagia from a haematologist’s point of view. Part I: initial evaluation. Haemophilia 2002; 8: 330-8.
31 Krause M, Ehrenforth S, Aygoeren-Puersuen E. et al. Bleeding disorders in 185 women with menorrhagia. Blood 2000; 96: 11 (abstract 198).
32 Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1236-9.
33 Lalonde A. Evaluation of surgical options in menorrhagia. Br J Obstet Gynaecol 1994; 101: 8-14
34 Lee CA. Women and inherited bleeding disorders: menstrual issues. Sem Hematol 1999; 36 (Suppl. 04) 21-7.
35 Leissinger C, Becton D, Cornell C. et al. High-dose DDAVP intranasal spray (Stimate^®) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001; 7: 258-66.
36 Lethagen S. Desmopressin in the treatment of women’s bleeding disorders. Haemophilia 1999; 5: 233-7.
37 Mannucci PM. Treatment of von Willebrand disease. Thromb Haemost 2001; 86: 149-53.
38 Miller CH, Dilley AB, Drewes C. et al. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost 2002; 87: 1082-3.
39 Nilsson IM. Von Willebrand’s disease – 50 years old. Acta Med Scand 1977; 201: 497-508.
40 Nishino M, Nishino S, Sugimoto M. et al. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy. Int J Hematol 1996; 64: 127-34.
41 Ong YL, Hull DR, Mayne EE. Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. Haemophilia 1998; 4: 63-5.
42 Prentice A. Medical management of menorrhagia. Br Med J 1999; 319: 1343-5.
43 Ragni MV, Bontempo FA, Cortese Hassett A. Von Willebrand disease and bleeding in women. Haemophilia 1999; 5: 313-7.
44 Ramsahoye BH, Davies SV, Dasani H. et al. Obstetric management in von Willebrand’s disease: a report of 24 pregnancies and a review of the literature. Haemophilia 1995; 1: 140-4.
45 Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76: 692-6.
46 Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991; 114: 563-8.
47 Rozeik Ch, Scharrer I. Defekt des von-Willebrand-Faktor-Proteins, gynäkologische und psychische Probleme bei Frauen mit von Willebrand-Syndrom. Gynäkol Geburtsh 1998; 3: 70-5.
48 Rybo G. Plasminogen activators in the endometrium. II. Clinical aspects – Variation in the concentration of plasminogen activators during the menstrual cycle and its relation to menstrual blood loss. Acta Obstet Gynecol Scand 1966; 45: 429-50.
49 Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 2089-93.
50 Siegel JE, Kouides PA. Menorrhagia from a haematologist’s point of view. Part II: management. Haemophilia 2002; 8: 339-47.
51 Takafuta T, Fujimura K, Shimomura T. et al. Precise diagnosis by gene analysis and successful management of delivery in three patients with type IIB von Willebrand disease. Int J Hematol 1994; 60: 163-72.
52 Walter O, Budde U, Muysers C. et al. Determination of high-molecular-weight von Willebrand factor multimers and their impact on specific VWF-activities in VWF/FVIII-concentrates. J Thromb Haemost 2003; 1 (Suppl): P1673.
53 Woo YL, White B, Corbally R. et al. Von Willebrand’s disease: an important cause of dysfunctional uterine bleeding. Blood Coagul Fibrinol 2002; 13: 89-93.